First-in-Class Therapeutics targeting Pan-Cancer Glycosaminoglycans
VAR2 Pharmaceuticals
We are a near clinical-stage Danish biotech company spun out from the University of Copenhagen. Meet our Team and read our Company History.
Our Mission is to develop novel therapies for cancer with a particular focus on hard-to-treat, recurrent and metastatic cancers.
A unique target for cancer therapies first identified by our founders.
Oncofetal Chondroitin Sulfate (CS) is a long sugar chain with a heavy sulfation pattern. This secondary modification is highly overexpressed in over 95% of cancers, with little to no expression in healthy tissue (except for placenta).
Portfolio of first-in-class antibodies with high affinity and specificity for oncofetal CS.
Vartumabs have tunable plasma half-life, can deliver complete tumor penetration, bind 95% of cancers and localize specifically and only to tumors in rodent models.
Vartumabs are suitable for most therapy types, including antibody-drug conjugates, radiotherapy, bispecifics and cell-based therapies.
We have compiled an extensive pre-clinical data package showing efficacy and safety of Vartumabs in antibody-drug conjugate and CD3-bispecific formats.
Our first clinical study will start in Q3 2024 and pave the way for efficacy trials focusing on a nominated ADC candidate.
In parallel, we are exploring the use of Vartumabs in other therapy types.